Shares in Germany’s Bayer have plunged after a U.S. jury found the Roundup weed killer was a substantial factor in a California man’s cancer — the second case that has gone against manufacturer Monsanto, acquired by Bayer last year.
Bayer AG shares dropped 13 percent to 60.66 euros ($68.84) in Frankfurt Wednesday. On Tuesday, a federal court jury in San Francisco ruled unanimously in a lawsuit against Monsanto. Attorneys say the trial, which will determine in a second phase whether the company is liable and if so, for how much, could help determine the fate of hundreds of similar lawsuits.
Monsanto says studies have established that Roundup’s active ingredient, glyphosate, is safe. It has appealed a separate U.S. court decision last year in favor of a man who used Roundup. Click here to read more.
- Bayer Shares Slide After Latest Roundup Cancer Ruling (Reuters)
- Dying From Cancer, This Man’s Case Has Stunning Repercussions in Canada (National Observer)
- Landmark EFSA Ruling Lays Ground Rules for New Transparency Law (IEG Policy)
- EU Court Annuls EFSA Decision Not to Release Glyphosate Data (IEG Policy)
- The Weed-Killing Chemical in a Monsanto Lawsuit Was Found in Beer and Wine (Business Insider)